Original Source

China's State Council has issued new guidelines for innovative drug pricing. Analysts expect multinational pharmaceutical companies to benefit from this policy, which aims to reward innovation and ease pricing tensions for domestic and international firms.

China Releases New Drug Pricing Policy

The State Council, China's cabinet, recently published new guidelines on innovative drug pricing. A bank analyst described these as "the most significant" in a decade, aiming to reward drug innovation and ease pricing tension for both domestic and multinational pharmaceutical companies. The framework document supports value-based pricing for patented innovative drugs, while generic drug prices will be driven down through market competition.

Expanded Market Opportunities for Multinational Pharma

These guidelines are expected to create a more favorable environment for multinational pharmaceutical companies to benefit in the Chinese market by reinforcing rewards for innovative drug development. According to SCMP, this policy is seen as a positive signal for the long-term growth of the pharmaceutical industry. The new measures could potentially reshape the competitive landscape of the Chinese pharmaceutical market, benefiting companies that invest in innovative technologies and product development.

*Source: SCMP (2026-04-22)*

Related Articles